Canine malignant melanoma alpha-3 integrin binding peptides
- PMID: 21722969
- PMCID: PMC4169883
- DOI: 10.1016/j.vetimm.2011.05.018
Canine malignant melanoma alpha-3 integrin binding peptides
Abstract
There is a need to develop novel targeted imaging and therapeutic agents that can aid in early diagnosis, detection of metastasis and treatment of melanoma. Alpha-3 integrin is overexpressed in 82% of metastatic melanomas in humans and may be a potential target for peptide ligands carrying therapeutic agents. Five melanoma cell lines were generated from canine primary oral and metastatic canine tumors, grown in mice, and validated with melanoma markers Melan A, S-100, Micropthalmia transcription factor (MITF), Tyrosinase, and MART-1. The melanoma cell lines were tested for binding affinity to previously published alpha-3 integrin-binding peptides containing the cdGXGXXc motif. Fluorescent conjugates of the alpha-3 integrin binding OA02 peptide were used to quantify receptor affinity in the cell lines, a specimen of canine primary oral melanoma, and melanoma xenografts. Alpha-3 integrin was expressed by all 5 canine melanoma cell lines. Four of the 5 lines as well as the primary canine tumor showed affinity to alpha-3 integrin binding peptides with the cdGXGXXc motif. Optical imaging of canine melanoma xenografts in nude mice indicates rapid, strong uptake of the optical tracer in the tumor with an average persistence of approximately 48 h. Ex vivo images showed high tumor-to-background ratio, with tumor signals more than twice that of the kidney and other vital organs. We propose that integrin alpha-3 integrin binding ligands could potentially become useful probes for imaging and delivery of cytotoxic agents for the treatment of melanoma.
Copyright © 2011 Elsevier B.V. All rights reserved.
Figures




Similar articles
-
Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02".Mol Imaging. 2005 Oct-Dec;4(4):439-47. doi: 10.2310/7290.2005.05169. Mol Imaging. 2005. PMID: 16285906
-
Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma.Vet Pathol. 2001 Jul;38(4):427-35. doi: 10.1354/vp.38-4-427. Vet Pathol. 2001. PMID: 11467477
-
Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas.Vet Res Commun. 2014 Mar;38(1):29-38. doi: 10.1007/s11259-013-9580-z. Epub 2013 Oct 15. Vet Res Commun. 2014. PMID: 24126842
-
The Comparative Oncology of Canine Malignant Melanoma in Targeted Therapy: A Systematic Review of In Vitro Experiments and Animal Model Reports.Int J Mol Sci. 2024 Sep 26;25(19):10387. doi: 10.3390/ijms251910387. Int J Mol Sci. 2024. PMID: 39408717 Free PMC article.
-
Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases.Vet Pathol. 2000 Nov;37(6):597-608. doi: 10.1354/vp.37-6-597. Vet Pathol. 2000. PMID: 11105949 Review.
Cited by
-
In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers.Vet Comp Oncol. 2018 Dec;16(4):571-579. doi: 10.1111/vco.12424. Epub 2018 Aug 8. Vet Comp Oncol. 2018. PMID: 30088848 Free PMC article.
-
Advances in diagnostic and treatment modalities for intracranial tumors.J Vet Intern Med. 2014 Jul-Aug;28(4):1165-85. doi: 10.1111/jvim.12370. Epub 2014 May 9. J Vet Intern Med. 2014. PMID: 24814688 Free PMC article. Review.
-
Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma.J Comp Pathol. 2018 Jul;162:50-58. doi: 10.1016/j.jcpa.2018.06.007. Epub 2018 Jul 18. J Comp Pathol. 2018. PMID: 30060843 Free PMC article.
-
A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells.Sci Rep. 2024 Aug 31;14(1):20263. doi: 10.1038/s41598-024-71181-0. Sci Rep. 2024. PMID: 39217266 Free PMC article.
-
G2/M arrest and mitotic slippage induced by fenbendazole in canine melanoma cells.Vet Med Sci. 2022 May;8(3):966-981. doi: 10.1002/vms3.733. Epub 2022 Jan 12. Vet Med Sci. 2022. PMID: 35020278 Free PMC article.
References
-
- Aina OH, Liu R, Sutcliffe JL, Marik J, Pan C-X, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007;4:631–651. - PubMed
-
- Aina OH, Marik J, Gandour-Edwards R, Lam KS. Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02". Mol Imaging. 2005a;4:439–447. - PubMed
-
- Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther. 2005b;4:806–813. - PubMed
-
- Aina OH, Sroka TC, Chen M-L, Lam KS. Therapeutic cancer targeting peptides. Biopolymers. 2002;66:184–199. - PubMed
-
- Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006;24:4582–4585. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials